Fill your pipeline with qualified pharmaceutical and life-sciences buyers.

Your pharmaceutical lead generation campaign’s list build, messaging, and account research finish during onboarding, so day one of the engagement is dialing day — we don’t ramp by quarter, pipeline pressure in pharma is real and waiting isn’t a plan. First qualified appointments typically land within the first week, with steady weekly cadence by week three. Your AEs see meetings on the calendar before most agencies have finished writing their kickoff deck.

Three-point standard, and all three must be met. Verified pain — the buyer has named a specific need (a capacity gap, a supplier they’ve outgrown, a therapeutic or compliance problem), not just mild curiosity. Decision authority — they can sign for it, or they’re one of two people who can. Active timeline — they’re evaluating in the next 90 days, not “sometime after the next budget cycle.” Anything short of all three doesn’t make your AE’s calendar.

Yes — that breadth is the point. Roughly half our pharma and life-sciences clients make the product (branded, generic, biotech, specialty) and half supply the value chain around it (CDMOs, CROs, lab equipment, packaging, cold chain, software). The motions are different — a CDMO sells capacity and quality systems, a distributor sells reach, a manufacturer sells a therapeutic story — so we map each prospect’s value-chain position before outreach and tune messaging to it. You’ll never have us pitching a contract manufacturer like a wholesaler.

We sequence engagement by stakeholder. Scientific and technical buyers enter first — the ones who’ll evaluate fit and approve the requirement. QA, regulatory, procurement, and finance enter later, at the qualification and terms stage. Our SDRs stay involved through the nurture phase so the handoff to your AE doesn’t reset the relationship. An 18-month evaluation can’t survive being thrown over a wall at month four; our model is built so it doesn’t have to.

Mid-market through enterprise — most clients land between $20M and $2B in revenue. The common thread isn’t size, it’s sales infrastructure: you need an existing AE, sales-engineer, or scientific-sales team capable of running a technical evaluation and closing once qualified meetings hit the calendar. If you’re earlier-stage without that closing motion in place, we’ll tell you upfront.

We run documented, consent-aware outreach and work inside your vendor-qualification, NDA, and GxP expectations — your compliance rules become our operating rules, not an afterthought. SDRs are briefed on what they can and can’t say about indications, off-label topics, and pricing, and every touch is logged in your CRM for an auditable trail. The goal is first contact that builds trust with a regulated buyer, not a flag in their procurement system.

Yes, and segmentation goes deeper than NAICS alone. We layer therapeutic area, value-chain position (manufacturer / CDMO / CRO / distributor / provider), modality (small molecule, biologic, cell & gene), GxP and accreditation status, revenue band, geography, and procurement maturity. The output is a tight target list of 200–800 accounts that actually fit your offer — not a generic “pharma” pull from a list vendor. Sloppy targeting is the single biggest reason outbound underperforms; we fix it before week one.

Monthly retainer, scoped to your target volume, account complexity, and cycle length. Enterprise targets, regulated buyers, and longer evaluations cost more to engage; smaller mid-market plays cost less. We don’t publish a rate card because each pharma client’s therapeutic focus, value-chain position, and offer look different, and a flat price would either overcharge half our clients or undercharge the other half. Book the assessment and you’ll get a written scope and quote within 30 minutes of the call.